10X Genomics (TXG)

Executive Summary

10X Genomics is the dominant player in single-cell and spatial genomics, providing essential tools that power over 10,000 publications. Its Chromium, Xenium, and Visium platforms enable researchers to map cellular biology at unprecedented resolution, driving breakthroughs in oncology, immunology, and drug development. With a growing installed base and increasing adoption in translational research, the company is well-positioned to benefit from the expansion of multiomics and AI-driven discovery. Financial performance has been solid, with revenue growth supported by recurring consumables sales and new product launches. However, competition from emerging technologies and macroeconomic headwinds pose risks. The company's focus on innovation and deep customer relationships provides a durable competitive advantage.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation Xenium In Situ platform with higher plexity and throughput70% success
• Q3 2026Fiscal Q2 2026 earnings beat and raised full-year guidance driven by strong consumables pull-through65% success
• Q4 2026Major pharmaceutical partnership for spatial genomics in clinical trials50% success